Novanta delivered solid second quarter financial results, meeting or exceeding expectations in revenue, margins, and profitability despite a challenging macroeconomic environment. The company achieved 10% growth in bookings and a book-to-bill ratio of 1.02, driven by mid-teens revenue growth in Advanced Surgery and Robotics & Automation businesses. New product introductions are on track to meet the $50 million sales target for the year.
GAAP Revenue increased by 2% to $241 million in Q2 2025 compared to the prior year.
Adjusted Diluted EPS was $0.76, exceeding the prior year's $0.73.
Adjusted EBITDA reached $52.2 million, up from $51.1 million in Q2 2024.
Organic Revenue Growth was (2.1)% for the quarter, impacted by acquisitions and foreign currency fluctuations.
Novanta expects sequential revenue and profit growth in the coming quarters, driven by innovation, robust customer demand in secular growth markets, and operational discipline. The company updated its full-year 2025 financial guidance and provided guidance for the third quarter of 2025.
Visualization of income flow from segment revenue to net income